ICVAX
/ Immuno Cure
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 03, 2025
YKYY-ICVAX-101: ICVAX as a HIV Therapeutic DNA Vaccine
(clinicaltrials.gov)
- P1 | N=45 | Active, not recruiting | Sponsor: Immuno Cure Holding (HK) Limited | Trial completion date: Jan 2025 ➔ Jun 2025
Trial completion date • Human Immunodeficiency Virus • Infectious Disease
October 04, 2024
YKYY-ICVAX-101: ICVAX As a HIV Therapeutic DNA Vaccine
(clinicaltrials.gov)
- P1 | N=45 | Active, not recruiting | Sponsor: Immuno Cure Holding (HK) Limited | Trial primary completion date: Jun 2024 ➔ Sep 2024
Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease
May 03, 2024
A novel PD1-enhanced DNA vaccine in PLWH under cART: a Phase 1, randomized, double-blinded, placebo-controlled, and dose-escalation study
(AIDS 2024)
- "These data suggest that ICVAX in ART-suppressed PLWH is safe and immunogenic and that larger clinical trials are needed to further investigate the effects of ICVAX on reservoirs."
Clinical • P1 data • Human Immunodeficiency Virus • Infectious Disease • Pain • CD4 • PD-1
February 12, 2024
ICVAX as a HIV Therapeutic DNA Vaccine
(clinicaltrials.gov)
- P1 | N=45 | Active, not recruiting | Sponsor: Shenzhen Immuno Cure Biomedical Company Limited
New P1 trial • Human Immunodeficiency Virus • Infectious Disease
1 to 4
Of
4
Go to page
1